Anatomic stage iii breast cancer ajcc v8 Trials in Boston, United States
Conditions / Anatomic stage iii breast cancer ajcc v8 / Boston, United States
Clinical trials for Anatomic stage iii breast cancer ajcc v8 investigate a range of treatment strategies and patient populations.
15 total trials for this combination
Showing top 10 of 15 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT02849496 | Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer | ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT05564377 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial | RECRUITING | — |
| NCT04379570 | Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT05812807 | Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab | RECRUITING | PHASE3 |
| NCT04593277 | Interactive Survivorship Program for the Improvement of Healthcare Resources in Adolescent and Young Adult Cancer Survivors, INSPIRE-AYA Study | COMPLETED | NA |
| NCT05564377 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial | RECRUITING | — |
| NCT04457596 | T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT06058377 | Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer | RECRUITING | — |
| NCT05710328 | Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial | ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT05564377 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial | RECRUITING | — |